Biogénesis Bagó closes 2024 with significant advancements in its global expansion strategy, including the inauguration of new offices in Vietnam and key milestones in Latin America, Asia, the Middle East, and North Africa. Over the past five years, this strategy has resulted in seven acquisitions, the opening of five new offices, the incorporation of more than 80 products, and an expansion to over 60 markets.
In 2024, Biogénesis Bagó reaffirmed its commitment to strengthening its presence in key markets and delivering innovative solutions for the animal health industry worldwide. In Latin America, the company inaugurated a facility in Campo Largo, Brazil. Designed to produce over 10 million doses of attenuated virus vaccines annually as well as other biotech solutions, this site solidifies Biogénesis Bagó’s position as the leading producer of veterinary vaccines in LATAM.
The company also made significant investments to enhance the production capacity across its facilities worldwide. These upgrades will elevate operational excellence, enabling faster and more efficient delivery of solutions to meet the demands of the world’s highly demanding markets.
Throughout the year, the biotechnological company made remarkable strides also promoting community health initiatives and, in collaboration with Fundación Mundo Sano, carried out rabies vaccination campaigns across Argentina. These efforts highlight Biogénesis Bagó’s dedication to addressing public health challenges through education and prevention. Also, the recently launched Pet Unit further strengthens this mission, demonstrating the company’s commitment to improving the well-being of pets and supporting their caregivers.
After years of providing high-quality biotechnological solutions to the Asian market, Biogénesis Bagó expanded its presence in this region with the inauguration of new regional offices in Vietnam, a dedicated space to grow its team and foster closer relationships with clients and partners.
Additionally, the company inaugurated a manufacturing site in Shanghai, China, in collaboration with a local partner. This facility focuses on reproductive and hormonal solutions while producing veterinary products for various species, including beef cattle, dairy, small ruminants, pigs, and beekeeping. Last October, their FMD vaccine, Bioaftogen, was launched in the Thai market in collaboration with CVG Tech and Advance Pharma, followed by its introduction in the Indonesian market in November together with Elanco. Earlier in the year, after obtaining the GMP/BPM certification granted by the Saudi Food & Drug Authority (SFDA), Bioaftogen also began being exported to Saudi Arabia.
As part of the company expansion strategy, Biogénesis Bagó advanced its technology transfer projects in South Korea and the Kingdom of Saudi Arabia, where two manufacturing sites for foot-and-mouth disease (FMD) vaccines are being developed. Additionally, its first technology transfer project for rabies vaccine production in collaboration with TECPAR initiated in Brazil.
“This year’s investments and expansion reinforce Biogénesis Bagó’s mission to provide world-class solutions to the animal health industry across the globe. The progress made in 2024 positions us to meet growing market demands in multiple regions while contributing to the principles of one health strategy” said Esteban Turic, CEO of the company.
Biogénesis Bagó also bolstered its relationships with global authorities, including the signing of a Memorandum of Understanding with the Arab Centre for the Studies of Arid Zones and Dry Lands (ACSAD). This agreement aims to collaborate on improving livestock productivity across the Middle East. Biogénesis Bagó's expertise in the prevention and control of foot-and-mouth disease was key to enabling the company to respond to the health emergency caused by outbreaks in Algeria and Libya, ensuring its vaccines were readily available to help contain the spread.
These achievements reflect Biogénesis Bagó’s unwavering commitment to solidifying its position as a global leader in animal health. As the company looks to 2025, its focus remains on innovation, excellence, and collaboration to meet the evolving demands of the animal health sector.
